LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Kupas, K. [1 ]
Kaspar, I. [1 ]
Baecke, V. [2 ]
Weisel, K. [3 ]
机构：
[1] Bristol Myers Squibb, Munich, Germany
[2] Ecker Ecker GmbH, Hamburg, Germany
[3] Univ Tubingen, Tubingen, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1256
引用
收藏
页码：514 / 515
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [22] Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Moreau, Philippe
    Palumbo, Antonio
    Belch, Andrew
    Schey, Stephen
    Sonneveld, Pieter
    Sternas, Lars
    Yu, Xin
    Amatya, Ramesh
    Monzini, Mara S.
    Zaki, Mohamed
    Jacques, Christian
    Miguel, Jesus San
    HAEMATOLOGICA, 2015, 100 (02) : E63 - E67
  • [23] Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma
    Fukushima, Toshihiro
    Nakamura, Takuji
    Iwao, Haruka
    Umehara, Hisanori
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (10) : 893 - 893
  • [24] Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
    Sung-Eun Lee
    Ji-Young Lim
    Da-Bin Ryu
    Tae Woo Kim
    Jae-Ho Yoon
    Byung-Sik Cho
    Ki-Seong Eom
    Yoo-Jin Kim
    Hee-Je Kim
    Seok Lee
    Seok-Goo Cho
    Dong-Wook Kim
    Jong-Wook Lee
    Woo-Sung Min
    Myungshin Kim
    Chang-Ki Min
    Cancer Immunology, Immunotherapy, 2016, 65 : 983 - 994
  • [25] Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma
    Murakami, Hirokazu
    Handa, Hiroshi
    Abe, Masahiro
    Iida, Sinsuke
    Ishii, Akihiro
    Ishikawa, Takayuki
    Ishida, Tadao
    Oota, Masatsugu
    Ozaki, Shuji
    Kosaka, Masaaki
    Sakai, Akira
    Sawamura, Morio
    Shimazaki, Chihiro
    Shimizu, Kazuyuki
    Takagi, Toshiyuki
    Hata, Hiroyuki
    Fukuhara, Takashi
    Fujii, Hiroshi
    Miyata, Akira
    Wakayama, Toshio
    Takatsuki, Kiyoshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (03) : 234 - 239
  • [26] Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
    Lee, Sung-Eun
    Lim, Ji-Young
    Ryu, Da-Bin
    Kim, Tae Woo
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong-Wook
    Min, Woo-Sung
    Kim, Myungshin
    Min, Chang-Ki
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (08) : 983 - 994
  • [27] Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma
    Dimopoulos, Meletios A.
    Roussou, Maria
    Gavriatopoulou, Maria
    Migkou, Magdalini
    Gkotzamanidou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Christoulas, Dimitrios
    Terpos, Evangelos
    Kastritis, Efstathios
    BLOOD, 2012, 120 (21)
  • [28] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
  • [29] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Dabkara, Deepak
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13
  • [30] PX-171-006, A PHASE IB DOSE-ESCALATION STUDY OF CARFILZOMIB plus LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Wang, M.
    Bensinger, W.
    Orlowski, R.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrail, N.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 157
12345